Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Mediators Inflamm, 2016
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823510/
“The clinical effect observed and the direct interaction between GLP-1 and the immune system raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions such as psoriasis.”
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis
Diabetologia, November 2011
https://pubmed.ncbi.nlm.nih.gov/21744074/
“Adiponectin significantly increased from baseline with tirzepatide compared with placebo (10, 15 mg).”
From here:
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Diabetes Care, April 2020
See here for more about the role of adiponectin:
Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction
International Journal of Molecular Sciences